-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the latest data from Minai.
com, in the first half of 2022, the sales of terminal proprietary Chinese medicine plasters in China's public medical institutions increased by more than 10%
year-on-year.
The market concentration of the TOP10 products is high, the total market share accounts for more than 70%, of which, 9 have sales of more than 100 million yuan, Yunnan white ointment ranks first, pain relief paste closely followed, both products are 1 billion yuan of large varieties, the first half of this year is again growth
.
From the perspective of growth rate, the growth rate of 4 products such as musk chasing wind pain cream and Shennong analgesic cream has exceeded 20%.
It is worth noting that 6 of the TOP10 products are exclusive, involving Yunnan Baiyao, Qizheng Tibetan Medicine, Lingrui Pharmaceutical, Jiangsu Kangyuan Sunshine Pharmaceutical and other enterprises
.
com, in the first half of 2022, the sales of terminal proprietary Chinese medicine plasters in China's public medical institutions increased by more than 10%
year-on-year.
The market concentration of the TOP10 products is high, the total market share accounts for more than 70%, of which, 9 have sales of more than 100 million yuan, Yunnan white ointment ranks first, pain relief paste closely followed, both products are 1 billion yuan of large varieties, the first half of this year is again growth
.
From the perspective of growth rate, the growth rate of 4 products such as musk chasing wind pain cream and Shennong analgesic cream has exceeded 20%.
It is worth noting that 6 of the TOP10 products are exclusive, involving Yunnan Baiyao, Qizheng Tibetan Medicine, Lingrui Pharmaceutical, Jiangsu Kangyuan Sunshine Pharmaceutical and other enterprises
.
Top 10 Chinese patent medicine plaster is out! Qi Zheng, Ling Rui, Kang Yuan.
.
.
6 exclusive products dominate the screen
.
.
6 exclusive products dominate the screen
Sales of plasters for proprietary Chinese medicines in recent years (100 million yuan)
Source: Competition pattern of drug terminals in China's public medical institutions
According to data from Minai.
com, in recent years, the market size of terminal proprietary Chinese medicine plasters in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) has steadily increased, exceeding the 7 billion yuan mark in 2021 and a year-on-year increase of more than 10%
in the first half of 2022.
com, in recent years, the market size of terminal proprietary Chinese medicine plasters in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) has steadily increased, exceeding the 7 billion yuan mark in 2021 and a year-on-year increase of more than 10%
in the first half of 2022.
From the perspective of sales channels, urban public hospitals and urban community centers are still the two main forces, with a total market share of more than 70%, while county-level public hospitals are growing rapidly
.
.
In the first half of 2022, the top 10 plaster products of proprietary Chinese medicines
Source: Competition pattern of drug terminals in China's public medical institutions
The product TOP10 market concentration is high, the total market share accounts for more than 70%, of which, 9 have sales of more than 100 million yuan, Yunnan white ointment ranks first, pain relief paste closely followed, both products are 1 billion yuan of large varieties, the first half of this year is again growth
.
From the perspective of treatment categories, swelling and pain relief drugs are the most, with 7.
It is worth noting that 6 of the top 10 products are exclusive, involving Yunnan Baiyao, Qizheng Tibetan Medicine, Lingrui Pharmaceutical, Jiangsu Kangyuan Sunshine Pharmaceutical and other enterprises
.
.
From the perspective of treatment categories, swelling and pain relief drugs are the most, with 7.
It is worth noting that 6 of the top 10 products are exclusive, involving Yunnan Baiyao, Qizheng Tibetan Medicine, Lingrui Pharmaceutical, Jiangsu Kangyuan Sunshine Pharmaceutical and other enterprises
.
In the first half of 2022, the top 10 brands of Chinese proprietary medicine patch plaster
Source: Competition pattern of drug terminals in China's public medical institutions
Among the top 10 brands, 8 have sales of more than 100 million yuan, and Yunnan Baiyao Wuxi Pharmaceutical's Yunnan White Ointment, Tibet Qizheng Tibetan Medicine's Analgesic Ointment, and Henan Lingrui Pharmaceutical's Tongluo Pain Relief Ointment ranked in the top three
.
In terms of quantity, Chongqing Xi'an Pharmaceutical has two products on the list, namely Musk Wind Chasing Pain Relief Cream and Musk Seahorse Wind Relief Ointment
.
.
In terms of quantity, Chongqing Xi'an Pharmaceutical has two products on the list, namely Musk Wind Chasing Pain Relief Cream and Musk Seahorse Wind Relief Ointment
.
Two products with more than 1 billion yuan led and reached a new high in the first half of the year
Sales of Yunnan white ointment in recent years (: 100 million yuan)
Source: Competition pattern of drug terminals in China's public medical institutions
Yunnan white ointment is used for bruises, bruises, swelling, rheumatic pain and other symptoms
.
According to data from Minai.
com, the sales of Yunnan white ointment in China's public medical institutions continued to climb after exceeding the 1 billion mark in 2019, with a year-on-year increase of 3.
84%
in the first half of 2022.
.
According to data from Minai.
com, the sales of Yunnan white ointment in China's public medical institutions continued to climb after exceeding the 1 billion mark in 2019, with a year-on-year increase of 3.
84%
in the first half of 2022.
In recent years, Yunnan Baiyao has focused on the "1+4+1" strategy to do a good job in enterprise transformation and development
.
The first "1" is to deepen the field of traditional Chinese medicine, "4" is to focus on the development of oral cavity, skin, bone injuries and women's care in four areas, and the second "1" is digital technology
.
At present, the company focuses on traditional Chinese medicine, oral intelligent care, dermatology, orthopedics and traumatology, etc.
, and has built a business layout covering the three-dimensional product groups such as traditional Chinese medicine natural medicine, Chinese medicine pieces, medical devices, daily chemical and personal care products, and health food, leading the transformation and upgrading
of enterprises.
.
The first "1" is to deepen the field of traditional Chinese medicine, "4" is to focus on the development of oral cavity, skin, bone injuries and women's care in four areas, and the second "1" is digital technology
.
At present, the company focuses on traditional Chinese medicine, oral intelligent care, dermatology, orthopedics and traumatology, etc.
, and has built a business layout covering the three-dimensional product groups such as traditional Chinese medicine natural medicine, Chinese medicine pieces, medical devices, daily chemical and personal care products, and health food, leading the transformation and upgrading
of enterprises.
Sales of analgesic patches in recent years (100 million yuan)
Source: Competition pattern of drug terminals in China's public medical institutions
Analgesic Patch is an exclusive product of Tibetan Qizheng Tibetan Medicine for acute and chronic sprains, bruises, bone hyperplasia, rheumatism and rheumatoid pain
.
According to data from Minai.
com, the sales scale of terminal pain relief patches in China's public medical institutions has steadily increased in recent years, exceeding 1 billion yuan for the first time in 2020, reaching a new high in 2021, and continuing to climb
steadily in the first half of 2022.
.
According to data from Minai.
com, the sales scale of terminal pain relief patches in China's public medical institutions has steadily increased in recent years, exceeding 1 billion yuan for the first time in 2020, reaching a new high in 2021, and continuing to climb
steadily in the first half of 2022.
It is understood that Qizheng Tibetan Medicine continues to promote and deepen the strategic layout of "one axis, two wings and three supports", further increase urban coverage and channel sinking, and continuously expand and enhance the company's brand influence
with academic and brand leadership.
Qizheng Tibetan Medicine said that analgesic series products are still the company's main products, and on the basis of analgesic ointment as a strategic variety, it will make white pulse ointment, Qingpeng ointment, and Ruyi treasure tablets to build the first brand
of integrated pain solutions.
Strengthen the organizational layout and terminal coverage of women's and children's products represented by Safflower Ruyi Pill and Pediatric Chaiqian Qingjie Granules, and continue to promote products in the fields of Tibetan medicine advantages such as cardiovascular and cerebrovascular and respiratory digestive systems
.
The company's star product analgesic paste is still in the leading position in the category of traditional Chinese medicine external analgesia, the national medical insurance variety Ruyi Treasure Tablets quickly cut into the market growth rate is high, and the sales of safflower Ruyi Pills have achieved sustained rapid growth
.
with academic and brand leadership.
Qizheng Tibetan Medicine said that analgesic series products are still the company's main products, and on the basis of analgesic ointment as a strategic variety, it will make white pulse ointment, Qingpeng ointment, and Ruyi treasure tablets to build the first brand
of integrated pain solutions.
Strengthen the organizational layout and terminal coverage of women's and children's products represented by Safflower Ruyi Pill and Pediatric Chaiqian Qingjie Granules, and continue to promote products in the fields of Tibetan medicine advantages such as cardiovascular and cerebrovascular and respiratory digestive systems
.
The company's star product analgesic paste is still in the leading position in the category of traditional Chinese medicine external analgesia, the national medical insurance variety Ruyi Treasure Tablets quickly cut into the market growth rate is high, and the sales of safflower Ruyi Pills have achieved sustained rapid growth
.
4 products with a growth rate of more than 20%! Musk chasing wind pain relief cream into "growth king"
From the perspective of growth rate, the growth rate of 4 products of musk chasing wind pain ointment, Shennong analgesic ointment, musk seahorse chasing ointment, and musk strong bone ointment all exceeded 20%.
Among them, only Musk Chasing Wind Pain Relief Cream is an exclusive product and the fastest growing product
in the TOP10.
In addition, Musk Strong bone paste is highly competitive, with 56 companies having production
approvals.
Among them, only Musk Chasing Wind Pain Relief Cream is an exclusive product and the fastest growing product
in the TOP10.
In addition, Musk Strong bone paste is highly competitive, with 56 companies having production
approvals.
Sales of musk chasing pain cream in recent years (: 100 million yuan)
Source: Competition pattern of drug terminals in China's public medical institutions
Musk chasing wind pain relief ointment is used for joint and muscle pain and sprain pain caused by cold and wet obstruction, and is an exclusive product
of Chongqing Hillan Pharmaceutical.
According to data from Minai.
com, in the first half of 2022, the sales of musk chasing pain cream in China's public medical institutions soared by 82.
59%.
Recently, Chongqing Xi'an Pharmaceutical has made frequent successes, and the company has been recognized as the 2022 National Intellectual Property Demonstration Enterprise and won the 2022 Chongqing Top 100 Manufacturing Private Enterprises List
.
Chongqing Xi'an Pharmaceutical said that in recent years, the company has vigorously implemented the talent strategy, brand strategy and innovation strategy, inherited the essence of Wu Shufang's culture for 300 years, while adhering to the scientific research strategy of "science and technology serving mankind, innovation promoting development", vigorously carrying out R&D and innovation, creating two core competitiveness in market access and marketing, and realizing the rapid development
of the company.
of Chongqing Hillan Pharmaceutical.
According to data from Minai.
com, in the first half of 2022, the sales of musk chasing pain cream in China's public medical institutions soared by 82.
59%.
Recently, Chongqing Xi'an Pharmaceutical has made frequent successes, and the company has been recognized as the 2022 National Intellectual Property Demonstration Enterprise and won the 2022 Chongqing Top 100 Manufacturing Private Enterprises List
.
Chongqing Xi'an Pharmaceutical said that in recent years, the company has vigorously implemented the talent strategy, brand strategy and innovation strategy, inherited the essence of Wu Shufang's culture for 300 years, while adhering to the scientific research strategy of "science and technology serving mankind, innovation promoting development", vigorously carrying out R&D and innovation, creating two core competitiveness in market access and marketing, and realizing the rapid development
of the company.
Sales of musk bone paste in recent years (: 100 million yuan)
Source: Competition pattern of drug terminals in China's public medical institutions
Musk strong bone ointment has analgesic, anti-inflammatory effects, used for rheumatic pain, joint pain, low back pain, neuralgia, muscle aches, etc
.
According to data from Minai.
com, the terminal sales of musk strong bone paste in China's public medical institutions have maintained a growth rate
of more than 20% in recent years.
At present, 56 enterprises have production approvals for this product, which is the most competitive variety in the TOP10 products, and the market share of Huangshi Health Materials Pharmaceutical, Anyang Zhongzhi Pharmaceutical and Huangshi Likang Pharmaceutical ranks in the top three
.
.
According to data from Minai.
com, the terminal sales of musk strong bone paste in China's public medical institutions have maintained a growth rate
of more than 20% in recent years.
At present, 56 enterprises have production approvals for this product, which is the most competitive variety in the TOP10 products, and the market share of Huangshi Health Materials Pharmaceutical, Anyang Zhongzhi Pharmaceutical and Huangshi Likang Pharmaceutical ranks in the top three
.
Source: Minainet database, company announcements
Note: Minai.
com's "Drug Terminal Competition Pattern of Public Medical Institutions in China", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics and village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
If there are any omissions, please feel free to point them out
.
com's "Drug Terminal Competition Pattern of Public Medical Institutions in China", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics and village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
If there are any omissions, please feel free to point them out
.
